1PaueiuUo P, Giannino A, De Michele M. Increased carotid artery intimamedia is associated a novel mutation of low - density lipoprotein receptor independently of major cardiovascular risk fac- tors[J]. Metabolism, 2003, 52 : 1 433 - 1 438.
2Bhagavatula MR, Fan C, Shen GQ, et al. Transcription factor MEF2A mutations in patients with coronary artery disease [ J ]. Hum Mol Genet, 2004,13:3 181 - 3 188.
3Poirier O, Nicaud V, Gariepy J, et al. Polymorphism R92Q of the tumour necrosis factor receptor 1 gene is associated with myocar- dial infarction and carotid intima - media thickness: the ECTIM, AXA, EVA and GENIC studies[J]. Eur J Hum Genet, 2004, 12 : 213-219.
4Sandmann T, Jensen LJ, Jakobsen JS, et al. A temporal map of transcription factor activity: mef2 directly regulates target genesat all stages of muscle development[J]. Dev. Cell, 2006, 10:797 - 807.
5Wang Q, Chen Q. Cardiovascular disease and congenital defects [J]. Nature Encyclopedia of Life Sciences, 2000, 3 : fi46 - fi57.
6Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly[J ]. Annu Rev Physiol, 2003, 65 : 45 - 79.
7Wolfrum C, Poy MN, Stoffel M. Apolipoprotein M is required for prebeta- HDL formation and cholesterol efflux to HDL and pro- tects against atherosclerosis[J]. Nat Med, 2005, 11:418 - 422.
8Barsyte - Lovejoy D, Galanis A, Clarity A, et al. ERK5 is targeted to myoeyte enhancer factor 2A (MEF2A) through a MAPK docking motif[J]. Bioehem J, 2004, 381 : 693 - 699.
9Dwyer JH, AUayee H, Dwyer KM, et al. Arachidonate 5 - lipoxy- genase promoter genotype0 dietary arachidonic acid, and atheroselerosis[ J ]. N Engl J Med, 2004, 350:29 - 37.
10Lu J. Regulation of skeletal myogenesis by association of the MEF2 transcription factor with class histone deacetylases [ J ]. Mol. Cell, 2000, 6:233 - 244.
